1-4 of 4
Hans G Cruz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Alex F. Herrera, Stephen M. Ansell, Pier Luigi Zinzani, John Radford, Kami J. Maddocks, Antonio Pinto, Graham P. Collins, Veronika Bachanova, Nancy L. Bartlett, Isabelle Bence-Bruckler, Mehdi Hamadani, Justin Kline, Jiri Mayer, Kerry J. Savage, Ranjana H. Advani, Paolo F. Caimi, René-Olivier Casasnovas, Tatyana A. Feldman, Brian T. Hess, Mariana Bastos-Oreiro, Sunil Iyengar, Árpád Szomor, William Townsend, Marc Andre, Jerzy Dyczkowski, Sandy Eisen, Andrzej Urban, Serafino Pantano, Hans G. Cruz, Luqiang Wang, Yanina Negievich, Jens Wuerthner, Carmelo Carlo-Stella
Journal: Blood
Blood (2022) 140 (Supplement 1): 3673–3677.
https://doi.org/10.1182/blood-2022-157583
Published: 2022
Journal Articles

CD25, Soluble CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Jerzy Dyczkowski, Alex F. Herrera, Carmelo Carlo-Stella, Pier Luigi Zinzani, Marie Toukam, Hans G. Cruz, Karin Havenith, Joseph Boni, Jens Wuerthner, Serafino Pantano
Journal: Blood
Blood (2022) 140 (Supplement 1): 9306–9308.
https://doi.org/10.1182/blood-2022-157748
Published: 2022
Journal Articles

Pharmacokinetic and Pharmacodynamic Correlates from the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Joseph Boni, Karin Havenith, Mehdi Hamadani, MD, Paolo F Caimi, MD, Katie Anderson, Tim Kopotsha, Hans G Cruz, Jens Wuerthner
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-137011
Published: 2020
Journal Articles

Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma

Alex F. Herrera, MD, Carmelo Carlo-Stella, MD, Graham P. Collins, MD DPhil, Kami J. Maddocks, MD, Nancy L. Bartlett, MD, Kerry J. Savage, MDMSc, Paolo F Caimi, Brian T. Hess, MD, Pier Luigi Zinzani, MD, Hans G Cruz, Luqiang Wang, Jay Feingold, Jens Wuerthner, Stephen M. Ansell, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–23.
https://doi.org/10.1182/blood-2020-137451
Published: 2020